Cyngn (CYN) said Friday that it priced a follow-on offering and plans to use the gross proceeds of about $20 million and cash at hand for working capital and other general corporate purposes.
Shares slumped 74% following a surge in intraday trading volume to over 23.3 million from a daily average of about 670,000.
Galectin Therapeutics (GALT) said Friday its trial evaluating belapectin in cirrhotic portal hypertension patients showed a 48.9% reduction in varices in the per-protocol population for the 2 mg/kg dose group. But, in the intent-to-treat population, the composite endpoint "did not reach statistical significance" even though the incidence of varices showed a 43.2% reduction.
Shares plunged 53% as intraday trading volume soared to over 7.7 million from the stock's daily average of about 294,000.
FingerMotion's (FNGR) shares sank 41% amid heavy trading after the technology company said it agreed with investors to raise $5 million in gross proceeds from the sale of common stock and warrants in a registered direct offering.
More than 3.2 million shares traded compared with a daily average of roughly 182,000.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.